Cosima Drewes

Cosima Drewes

Auto-generated profile, based on publicly available information

Cosima Drewes

University Ulm, Ulm, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 November 2025 in Leukemia
Verified
Journal Article
Closed access
PDF file
KKK. S. Kurz
K. S. Kurz
AZA. Zamo
A. Zamo
CDC. Drewes
C. Drewes
EMEwelina Madej
Ewelina Madej
CLCamille Laurent
Camille Laurent
HHHeike Horn
Heike Horn

29 April 2026 in HemaSphere
Verified
Journal Article
Open access
CDCosima Drewes
Cosima Drewes
CLCristina López
Cristina López
JMJuan Emilio Martínez Manjón
Juan Emilio Martínez Manjón
NONnamdi Okeke
Nnamdi Okeke
BJBilly Jebaraj
Billy Jebaraj
RSReiner Siebert
Reiner Siebert
Approximately 1% of chronic lymphocytic leukemia (CLL) cases harbor a translocation juxtaposing the immunoglobulin heavy chain ( IGH ) and B‐cell lymphoma 3 ( BCL3 ) loci. Aiming at comprehensive molecular characterization of IGH :: BCL3‐ positive B‐cell neoplasms, we here investigated samples from 84 patients using fluorescence in situ hybridization (FISH), whole‐genome and targeted sequencing, and DNA methylation analyses. Junctional sequences obtained in 27 patients showed breakpoints upstream of BCL3 in all CLL cases. IGH breaks were presumably driven by aberrant class‐switch recombination in 26/27 cases, frequently involving IGHA (12/26). Notably, 95% (78/82) of patients carried an unmutated IGHV with significant CLL stereotype subset #8 enrichment. Trisomy 12 (61%, 51/83) and mutations affecting NOTCH1 (32%, 25/79), BRAF (14%, 11/79), and FBXW7 (14%, 11/79) were frequent aberrations. DNA methylation analysis assigned 77% (51/66) of patients with IGH :: BCL3‐ translocation with at least 60% tumor cell content to the naive B‐cell‐like group but unraveled a distinct and during follow‐up stable signature resembling in part plasma cell‐like epigenetic features. A binary DNA methylation classifier using 20 CpGs could distinguish IGH :: BCL3 ‐translocated CLL samples from other CLL subtypes. In an efficacy cohort of 3832 previously untreated patients from GCLLSG trials, IGH::BCL3 was associated with shorter progression‐free survival (PFS) and overall survival (OS) in 28 patients when treated with chemoimmunotherapy, but not in those receiving venetoclax. Our findings highlight the genetic and epigenetic homogeneity of IGH :: BCL3 ‐translocated CLL samples and their differences from other types of CLL, suggesting IGH :: BCL3 leukemic B‐cell neoplasms to be a biological distinct type within the spectrum of mature lymphatic leukemia/CLL.

23 April 2026 in Leukemia
Verified
Journal Article
Open access
PDF file
CDCosima Drewes
Cosima Drewes
CLCristina López
Cristina López
NONnamdi Okeke
Nnamdi Okeke
BJBilly Michael Chelliah Jebaraj
Billy Michael Chelliah Jebaraj
CWChristoph Wiegreffe
Christoph Wiegreffe
RSReiner Siebert
Reiner Siebert
Activation of oncogenes by hijacking immunoglobulin gene loci ( IG ) enhancers via chromosomal translocation is a common pathogenetic mechanism in B-cell malignancies, affecting 5–10% of chronic lymphocytic leukemia (CLL). The oncogenic partners in many of these cases remain unidentified. Therefore, we conducted a comprehensive analysis of 144 CLL samples with IGH- translocation excluding IGH :: BCL2 , IGH :: CCND1 , IGH :: BCL3 and IGH :: MYC . By combining fluorescence in situ hybridization (FISH) with whole-genome, targeted sequencing, and RNA expression profiling, we identified 25 IG -translocation partners; 12 were previously unreported. Of 142 cases, 107 (75%) displayed an unmutated IGHV . Genetic profiling showed a heterogenous distribution of chromosomal aberrations and recurrently mutated genes across the groups. Of 41 informative cases, 32 (78%) exhibited breakpoints driven by aberrant class-switch recombination (CSR), with prominent involvement of IGHM (9/41) and IGHG3 (9/41). Three cases with unmutated IGHV carried a juxtaposition of the IGH locus 5’ to the intact NKX2.6 gene in chromosome 8p21.2 due to illegitimate VDJ recombination, associated with significant ectopic upregulation of NKX2.6 transcriptional expression (FDR < 0.001, logFC: 15). Similarly, METRNL , located at the telomere of chromosome 17q25, was identified as a translocation partner gene in four cases. Our findings expand the spectrum of the oncogenic translocation partners targeting IGH in CLL.

5 June 2026 in Blood Advances
Verified
Journal Article
Open access
JQJialei Qi
Jialei Qi
WLWen Li
Wen Li
RDRashmi Priyadharshini Dheenadayalan
Rashmi Priyadharshini Dheenadayalan
DYDeyan Yordanov Yosifov
Deyan Yordanov Yosifov
CDCosima Drewes
Cosima Drewes
BJBilly Michael Chelliah Jebaraj
Billy Michael Chelliah Jebaraj
Bruton tyrosine kinase inhibitors (BTKi) are successful in treatment of chronic lymphocytic leukemia (CLL), yet acquired resistance remains a challenge. In our study, REC-1 cells that acquired resistance to BTKi tirabrutinib by long-term treatment gained a splice-site mutation (SSM) c.2236-1G>T in PLCG2. Notably, a deletion spanning c.2236-23_2238 at the same splice site (SSD) was identified in CLL from a patient who had disease progression during ibrutinib therapy. These alterations resulted in the exon-skipped variant, ∆21, which exhibited enhanced phospholipase activity. PLCG2 SSM REC-1 exhibited increased anti-IgM-mediated calcium flux and resistance to BTK inhibition but retained sensitivity to PLCγ inhibitors. By analyzing additional primary CLL samples, we identified widespread expression of two additional exon-skipped variants, ∆22 and ∆20-22, independent of PLCG2 genetic alterations. The active ∆20-22, which is also described in PLCG2-associated immune dysregulation (PLAID), was predominantly present in CLL compared to healthy donor samples. Expression analysis in CLL cells isolated from patients before and after targeted treatments revealed a decrease in expression of ∆20-22 post-venetoclax (p = 0.02)while no change in expression was observed after ibrutinib treatment, indicating that these variants may persist in the presence of ibrutinib but might be lost in the absence of drug selection pressure. Our study reveals novel PLCG2 splice-site alterations and exon-skipped variants beyond the classical BTK or PLCG2 mutations, to have a potential role in BTKi resistance and inform treatment selection.